Loading...

Pasadena Site And Tech Integration Will Unlock Future Opportunities

Published
24 Sep 24
Updated
28 Apr 26
Views
178
28 Apr
US$52.07
AnalystConsensusTarget's Fair Value
US$75.00
30.6% undervalued intrinsic discount
Loading
1Y
-4.3%
7D
5.9%

Author's Valuation

US$7530.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Last Update 28 Apr 26

SCL: Stable Margins And Buybacks Will Support Long-Term Dividend Upside

Analysts kept their fair value estimate steady at $75, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions. This indicates a largely unchanged view of Stepan's longer term potential.

What's in the News

  • Reported unaudited goodwill impairment of $6,245,000 for the three months ended December 31, 2025, which directly affects reported earnings for that quarter (Key Developments).
  • Updated on the share repurchase program announced on October 20, 2021, with a total of 251,120 shares repurchased for $25.06 million, representing 1.12% of shares under that authorization (Key Developments).
  • Confirmed that between October 1, 2025 and December 31, 2025, the company did not repurchase additional shares under the existing buyback authorization (Key Developments).

Valuation Changes

  • Fair Value: Kept steady at $75, signalling no material change in the overall valuation outcome from the model.
  • Discount Rate: Adjusted slightly from 8.31% to 8.33%, reflecting a very small change in the assumed risk profile.
  • Revenue Growth: Held effectively unchanged at about 4.37%, indicating consistent expectations for future top line expansion in the model.
  • Net Profit Margin: Maintained at roughly 3.69%, with only a minor numerical refinement to the projected profitability assumption.
  • Future P/E: Left effectively flat, moving fractionally from 21.41x to 21.43x and implying a stable view on Stepan's long term earnings multiple.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Growth in specialty alkoxylation and strategic end markets indicates potential for continued revenue and earnings increases across key segments.
  • The startup of the new Texas site and focus on acquiring over 400 new customers can boost volume growth and supply chain savings.
  • Global macroeconomic uncertainties and competitive pressures could negatively impact revenue, margins, and cash flow across multiple segments for Stepan.

Catalysts

About Stepan
    Produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products worldwide.
What are the underlying business or industry changes driving this perspective?
  • The startup of the new Pasadena, Texas site is expected to reach full contribution in the second half of 2025, which could boost volume growth and supply chain savings. This is likely to impact revenue and margins positively.
  • Strong growth in specialty alkoxylation, showing 19% growth in Q1, suggests continued revenue growth and earnings improvement in the Surfactants business with enhanced customer and product mix.
  • The broad-based volume growth in key strategic end markets, including double-digit growth in agricultural and oilfield sectors, indicates potential for continued revenue and earnings growth across these segments.
  • The strategic focus on new customer acquisition, especially with over 400 new customers in tier 2 and tier 3, should drive revenue growth and improve net margins due to a more diversified and high-value customer base.
  • The successful integration of new technologies and products in the insulation and spray foam markets in the Polymers segment suggests potential for future revenue growth and improved margins as these markets expand.
Stepan Earnings and Revenue Growth

Stepan Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Stepan's revenue will grow by 4.4% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 2.0% today to 3.7% in 3 years time.
  • Analysts expect earnings to reach $97.9 million (and earnings per share of $4.25) by about April 2029, up from $46.9 million today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.2x on those 2029 earnings, down from 25.5x today. This future PE is lower than the current PE for the US Chemicals industry at 31.6x.
  • Analysts expect the number of shares outstanding to grow by 0.25% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 8.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • The high interest rate environment and global macroeconomic uncertainties are restraining Rigid Polyol growth in North America and Europe, potentially impacting revenues and net margins.
  • Negative free cash flow of $25.8 million due to high working capital requirements and increased raw material purchases could pressure financials such as cash flow and net earnings if not addressed.
  • The Surfactants segment faces risks from raw material cost increases that are passed through to selling prices; any inability to effectively manage these costs could compress profit margins.
  • Competitive pressures and a decline in selling prices in the Polymers segment, despite volume growth, could lead to lower overall revenue and operating income.
  • Tariffs and trade uncertainties may create inflationary pressures and indirect impacts on consumer demand, which could result in decreased sales volumes and negatively affect earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $75.0 for Stepan based on their expectations of its future earnings growth, profit margins and other risk factors.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.7 billion, earnings will come to $97.9 million, and it would be trading on a PE ratio of 22.2x, assuming you use a discount rate of 8.3%.
  • Given the current share price of $52.66, the analyst price target of $75.0 is 29.8% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Stepan?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives